Pharmacy Drugs
Recent Posts
- Democrats Push Medical Device Liability Bill
- FDA Investigates Heparin Link in Two Delaware Deaths
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Random Posts
- Study Shows Easy Strength Training Exercise May Help Treat Tennis Elbow
- Measuring Brain's Memory Centers May Help Predict Alzheimer's
- Approval For Use Of RISPERDAL CONSTA As Both A Monotherapy And Adjunctive Therapy In The Maintenance Treatment Of Bipolar I Disorder Granted By FDA
- FDA Approves Implant for Retinal Vein Occlusion
- Efforts To Quickly Develop Swine Flu Vaccine Reported In GEN
- Excellence In Oncology Awards 2009 Now Open For Entry
- SNM's Clinical Trials Network Expands European Membership Of PET Biomarker Manufacturers
- Industry Asked To Fund Government Purchasing, Australia
- New Stem Cell Research Unlocks Unknown Therapies
- Dangerous Legal Loophole Must Be Closed, Society Warns
Versartis Presents Preclinical Data For Novel Type 2 Diabetes Drug
Posted by: admin in Pharmacy Drugs on September 30th, 2009
Versartis, Inc. today presented preclinical data demonstrating the potential for monthly dosing of its lead product, VRS-859 (exenatide-XTEN), for the treatment of type 2 diabetes. The data were presented by Jeffrey Cleland, Ph.D., Founder and Chief Executive Officer of Versartis, at the IBC Protein Engineering & Design Conference in San Diego.
In his talk, “Half-life Extension and In Vivo Biological Activity of Peptide and Protein Therapeutics,” Dr. Cleland presented VRS-859 preclinical data in models of diabetes and pharmacokinetics in mice, rats, dogs and monkeys. Versartis has begun development activities for VRS-859 including manufacturing and regulatory meetings. A clinical study of VRS-859 in patients with type 2 diabetes is planned for the first half of 2010.
Versartis is also finalizing lead selection for VRS-317 (human growth hormone-XTEN), a monthly dosage form. Dr. Cleland presented preclinical proof of concept and pharmacokinetic data. Versartis plans to begin Phase I clinical trials of VRS-317 in patients with growth hormone deficiency in the second half of 2010.
In addition to the reduced dosing frequency, Versartis’ XTEN products enable room temperature stability and low cost manufacturing. The XTEN properties allow for co-formulation and co-administration of proteins and peptides that are normally incompatible. Versartis is conducting research on combination products for metabolic disease to exploit these novel properties.
“Versartis is focusing on treatments for metabolic and endocrine diseases that currently require daily or weekly dosing,” explained Dr. Cleland. “Our results to date demonstrate the potential for monthly dosing of our compounds. The potential for improved convenience along with other XTEN properties provide a distinct advantage for Versartis’ products over other products on the market or in development.”
Source
Versartis, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.